Literature DB >> 16462301

Economic impact of the community-acquired methicillin-resistant Staphylococcus aureus epidemic on the Driscoll Children's Health Plan.

Kevin Purcell1, Jaime Fergie, Mary Dale Peterson.   

Abstract

Cellulitis and abscess accounted for increasing percentages of inpatient (4.6-11.1%), outpatient (0.6-1.2%) and total (1.7-3.3%) expenses from 2001 through 2004. The per member per month expenses attributed to cellulitis and abscess increased from $0.74 in 2001 to $1.19 in 2004. The epidemic of community-acquired methicillin-resistant Staphylococcus aureus infections in children has had a significant economic impact on the Driscoll Children's Health Plan.

Entities:  

Mesh:

Year:  2006        PMID: 16462301     DOI: 10.1097/01.inf.0000199304.68890.60

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  4 in total

1.  Trends in resource utilization for hospitalized children with skin and soft tissue infections.

Authors:  Michelle A Lopez; Andrea T Cruz; Marc A Kowalkowski; Jean L Raphael
Journal:  Pediatrics       Date:  2013-02-25       Impact factor: 7.124

Review 2.  Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic.

Authors:  Michael Z David; Robert S Daum
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

3.  The economic burden of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA).

Authors:  B Y Lee; A Singh; M Z David; S M Bartsch; R B Slayton; S S Huang; S M Zimmer; M A Potter; C M Macal; D S Lauderdale; L G Miller; R S Daum
Journal:  Clin Microbiol Infect       Date:  2012-06-19       Impact factor: 8.067

4.  Non-bullous Impetigo: Incidence, Prevalence, and Treatment in the Pediatric Primary Care Setting in Italy.

Authors:  Elisa Barbieri; Gloria Porcu; Daniele Dona'; Nathalie Falsetto; Mirella Biava; Antonio Scamarcia; Luigi Cantarutti; Anna Cantarutti; Carlo Giaquinto
Journal:  Front Pediatr       Date:  2022-03-31       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.